Biogen shares are trading higher after the company announced it plans a regulatory filing for Aducanumab in Alzheimer's disease following new analysis. The terminated Phase 3 EMERGE study met its primary endpoint and the company now believes a subset of patients in the Phase 3 ENGAGE study also support the findings of EMERGE.